Moreover, in CHC patients, the administration of a γ-secretase inhibitor that suppresses the Notch pathway significantly decreased IL-22 production and antimicrobial responses, suggesting that the modulation of the Notch–Th22 axis may be critical for CHC therapy [175]. This evidence concerns the gene IL22 and cryohydrocytosis.